Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study

BACKGROUND: Triplet and doublet regimens of encorafenib plus cetuximab with and without binimetinib, respectively, were approved in Japan for unresectable, metastatic, BRAF V600E-mutated colorectal cancer (mCRC) that had progressed after 1–2 prior chemotherapies. This early post-marketing phase vigi...

Descripción completa

Detalles Bibliográficos
Autores principales: Sakata, Hidenori, Murase, Maki, Kato, Takeshi, Yamaguchi, Kensei, Sugihara, Kenichi, Suzuki, Shigenobu, Yoshino, Takayuki
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Nature Singapore 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823055/
https://www.ncbi.nlm.nih.gov/pubmed/36355316
http://dx.doi.org/10.1007/s10147-022-02264-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823055/
https://www.ncbi.nlm.nih.gov/pubmed/36355316
http://dx.doi.org/10.1007/s10147-022-02264-z

Ejemplares similares